TARS2
Basic information
Region (hg38): 1:150487414-150507602
Previous symbols: [ "TARSL1" ]
Links
Phenotypes
GenCC
Source:
- combined oxidative phosphorylation defect type 21 (Supportive), mode of inheritance: AR
- combined oxidative phosphorylation defect type 21 (Moderate), mode of inheritance: AR
- combined oxidative phosphorylation defect type 21 (Strong), mode of inheritance: AR
- Leigh syndrome (Limited), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Combined oxidative phosphorylation deficiency 21 | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Biochemical; Musculoskeletal; Neurologic | 24827421 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TARS2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 43 | 49 | ||||
missense | 78 | 87 | ||||
nonsense | 5 | |||||
start loss | 1 | |||||
frameshift | 2 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 2 | |||||
splice region | 1 | 8 | 9 | 1 | 19 | |
non coding | 33 | 40 | 74 | |||
Total | 0 | 3 | 88 | 82 | 47 |
Variants in TARS2
This is a list of pathogenic ClinVar variants found in the TARS2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-150487417-CTGTT-C | not specified | Benign (Aug 01, 2016) | ||
1-150487429-G-A | Likely benign (Jun 23, 2021) | |||
1-150487451-A-T | Uncertain significance (Dec 27, 2021) | |||
1-150487455-C-T | Uncertain significance (Sep 24, 2021) | |||
1-150487458-T-A | Uncertain significance (Aug 31, 2022) | |||
1-150487459-G-C | Likely benign (Jun 09, 2023) | |||
1-150487481-C-T | Inborn genetic diseases | Uncertain significance (May 27, 2022) | ||
1-150487499-G-A | Combined oxidative phosphorylation defect type 21 • Inborn genetic diseases | Uncertain significance (Jun 02, 2023) | ||
1-150487511-C-T | Uncertain significance (Feb 04, 2023) | |||
1-150487651-T-TCTAA | Benign (Feb 04, 2019) | |||
1-150487692-A-G | Benign (Jun 14, 2018) | |||
1-150487872-C-T | not specified • TARS2-related disorder | Benign (Jan 29, 2024) | ||
1-150487882-T-A | Inborn genetic diseases | Uncertain significance (Nov 06, 2023) | ||
1-150487892-A-G | Uncertain significance (Jun 01, 2018) | |||
1-150487932-A-G | not specified | Likely benign (Sep 29, 2017) | ||
1-150487934-A-G | Uncertain significance (Aug 13, 2022) | |||
1-150487950-G-A | Inborn genetic diseases | Conflicting classifications of pathogenicity (Aug 22, 2022) | ||
1-150487962-A-G | Likely benign (Aug 19, 2023) | |||
1-150487968-G-A | Likely benign (Oct 27, 2023) | |||
1-150487977-G-A | Likely benign (Sep 05, 2023) | |||
1-150487981-T-C | Inborn genetic diseases | Uncertain significance (May 31, 2023) | ||
1-150487982-C-G | Likely pathogenic (Apr 20, 2023) | |||
1-150487984-C-G | Uncertain significance (Jul 21, 2022) | |||
1-150488027-C-T | Uncertain significance (Oct 13, 2023) | |||
1-150488044-C-T | Inborn genetic diseases | Uncertain significance (Sep 26, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
TARS2 | protein_coding | protein_coding | ENST00000369064 | 18 | 20192 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.22e-12 | 0.979 | 125688 | 0 | 59 | 125747 | 0.000235 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.77 | 323 | 426 | 0.758 | 0.0000254 | 4598 |
Missense in Polyphen | 102 | 168.8 | 0.60428 | 1805 | ||
Synonymous | 0.153 | 163 | 166 | 0.985 | 0.00000892 | 1512 |
Loss of Function | 2.39 | 26 | 42.9 | 0.606 | 0.00000225 | 442 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000387 | 0.000387 |
Ashkenazi Jewish | 0.000498 | 0.000496 |
East Asian | 0.000381 | 0.000381 |
Finnish | 0.0000925 | 0.0000924 |
European (Non-Finnish) | 0.000238 | 0.000237 |
Middle Eastern | 0.000381 | 0.000381 |
South Asian | 0.000261 | 0.000261 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the attachment of threonine to tRNA(Thr) in a two-step reaction: threonine is first activated by ATP to form Thr-AMP and then transferred to the acceptor end of tRNA(Thr). Also edits incorrectly charged tRNA(Thr) via its editing domain. {ECO:0000269|PubMed:26811336}.;
- Disease
- DISEASE: Combined oxidative phosphorylation deficiency 21 (COXPD21) [MIM:615918]: A mitochondrial disorder characterized by a lethal encephalomyopathy. Shortly after birth, affected individuals manifest axial hypotonia, limb hypertonia, psychomotor delay, and increased serum lactate. Additional features include subsarcolemmal lipofuscin-positive deposits in muscle, cerebral spongiosis, and hepatic steatosis. {ECO:0000269|PubMed:24827421, ECO:0000269|PubMed:26811336}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Aminoacyl-tRNA biosynthesis - Homo sapiens (human);tRNA Aminoacylation;Translation;Metabolism of proteins;tRNA charging;Mitochondrial tRNA aminoacylation;Glycine, serine, alanine and threonine metabolism
(Consensus)
Recessive Scores
- pRec
- 0.0841
Intolerance Scores
- loftool
- 0.405
- rvis_EVS
- -0.27
- rvis_percentile_EVS
- 34.82
Haploinsufficiency Scores
- pHI
- 0.161
- hipred
- Y
- hipred_score
- 0.520
- ghis
- 0.519
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.918
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Tars2
- Phenotype
Gene ontology
- Biological process
- threonyl-tRNA aminoacylation;mitochondrial threonyl-tRNA aminoacylation;aminoacyl-tRNA metabolism involved in translational fidelity
- Cellular component
- cellular_component;cytoplasm;mitochondrial matrix
- Molecular function
- aminoacyl-tRNA editing activity;threonine-tRNA ligase activity;ATP binding;protein homodimerization activity